JATT Acquisition (NYSE:JATT) Reports Regulation FD Disclosure

On November 25, 2024, Zura Bio Limited (“ZURA”, the “Company”) issued a press release as part of its regulatory FD disclosure. The press release, attached as Exhibit 99.1 to the current Form 8-K report, contains pertinent information that the Company wants to make available to the public.

By submitting this Form 8-K, Zura Bio Limited does not admit to the materiality of any information contained within due to Regulation FD requirements.

It should be noted that the details furnished in Item 7.01 of this Form 8-K and the accompanying Exhibit 99.1 are not to be considered filed under Section 18 of the Securities Exchange Act of 1934, unless explicitly stated by the Company. They are also not subject to the liabilities as prescribed in that section unless the Company expressly confirms the information to be “filed” under the Exchange Act or incorporates it by reference into another filing under the Securities Act of 1933 or the Exchange Act.

Furthermore, in compliance with Item 9.01, the Company provides the following exhibit:

– Exhibit 99.1: Press Release dated November 25, 2024

Additionally, there is a Cover Page Interactive Data File (104) embedded within the Inline XBRL document.

In conclusion, the report has been duly signed on behalf of Zura Bio Limited on November 25, 2024, by Kim Davis, the Chief Legal Officer.

By: /s/ Kim Davis
Kim Davis
Chief Legal Officer

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read JATT Acquisition’s 8K filing here.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector.